Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Xynomic Completes Pre-IND Conference with US FDA for RAF Inhibitor

publication date: Jun 12, 2019

Xynomic, a US-China oncology pharma, recently completed a pre-IND meeting with the US FDA for its pan-RAF inhibitor XP-102. It said the FDA provided valuable advice on its clinical development plan for the candidate. The company, which thinks XP-102 may prove to be best-in-class, hopes to file for XP-102 in the second half of 2019. In 2017, Xynomic announced a $502 million agreement to acquire global rights to the molecule from Boehringer Ingelheim. More details...

Stock Symbol: (NSDQ: XYN)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital